Fusion Antibodies PLC Cash Flow-to-Debt Ratio
Fusion Antibodies PLC cash flow-to-debt ratio. Fusion Antibodies PLC (FAB) has a Cash Flow-to-Debt Ratio of -0.53x as of September 2025, meaning its operating cash flow of GBX-575.00K could theoretically repay -1% of its total liabilities (GBX1.09 Million) in one year. Check Fusion Antibodies PLC cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Fusion Antibodies PLC (2015–2025)
Cash flow-to-debt ratio of Fusion Antibodies PLC from 2015 to 2025. Historical debt coverage capacity for Fusion Antibodies PLC across 11 annual periods. Check Fusion Antibodies PLC (FAB) reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Fusion Antibodies PLC Cash Flow-to-Debt Ratio by Year (2015–2025)
Fusion Antibodies PLC cash flow-to-debt ratio by year from 2015 to 2025. Year-by-year debt coverage analysis for Fusion Antibodies PLC. For the full cash flow conversion analysis, see Fusion Antibodies PLC operating cash flow efficiency.
| Year | CF-to-Debt Ratio | Operating CF (GBX) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -2.09x | GBX-1.36 Million | GBX654.00K | ▲ +26.1% |
| 2024 | -2.82x | GBX-1.77 Million | GBX627.00K | ▼ -51.0% |
| 2023 | -1.87x | GBX-1.75 Million | GBX939.00K | ▼ -597.2% |
| 2022 | -0.27x | GBX-330.00K | GBX1.23 Million | ▲ +74.8% |
| 2021 | -1.06x | GBX-1.15 Million | GBX1.08 Million | ▼ -686.2% |
| 2020 | -0.14x | GBX-166.00K | GBX1.23 Million | ▲ +89.1% |
| 2019 | -1.24x | GBX-1.10 Million | GBX888.53K | ▼ -1114.6% |
| 2018 | 0.12x | GBX77.19K | GBX633.59K | ▲ +246.8% |
| 2017 | -0.08x | GBX-37.37K | GBX450.22K | ▼ -109.9% |
| 2016 | 0.84x | GBX346.57K | GBX411.43K | ▲ +193.3% |
| 2015 | -0.90x | GBX-182.05K | GBX201.67K | — |